| Literature DB >> 34178944 |
Ahmed M El-Saghier1, Mohamed El-Naggar2, Abdel Haleem M Hussein3, Abu-Bakr A El-Adasy3, M Olish3, Aboubakr H Abdelmonsef4.
Abstract
A new series of class="Chemical">quinoline derivatives 5-12 were efficiently synthesized via one-pot multicomponent reaction (MCR) of <class="Chemical">span class="Chemical">resorcinol, aromatic aldehydes, β-ketoesters, and aliphatic/aromatic amines under solvent-free conditions. All products were obtained in excellent yields, pure at low-cost processing, and short time. The structures of all compounds were characterized by means of spectral and elemental analyses. In addition, all the synthesized compounds 5-12 were in vitro screened for their antioxidant and antibacterial activity. Moreover, in silico molecular docking studies of the new quinoline derivatives with the target enzymes, human NAD (P)H dehydrogenase (quinone 1) and DNA gyrase, were achieved to endorse their binding affinities and to understand ligand-enzyme possible intermolecular interactions. Compound 9 displayed promising antioxidant and antibacterial activity, as well as it was found to have the highest negative binding energy of -9.1 and -9.3 kcal/mol for human NAD (P)H dehydrogenase (quinone 1) and DNA gyrase, respectively. Further, it complied with the Lipinski's rule of five, Veber, and Ghose. Therefore, the quinoline analogue 9 could be promising chemical scaffold for the development of future drug candidates as antioxidant and antibacterial agents.Entities:
Keywords: antibacterial; antioxidant; chromenoquinolines; molecular docking; multicomponent reaction
Year: 2021 PMID: 34178944 PMCID: PMC8222571 DOI: 10.3389/fchem.2021.679967
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
SCHEME 1Synthesis of quinoline derivative 5a–d under solvent-free conditions.
SCHEME 2Synthesis of quinoline 6.
SCHEME 3Schematic representation of the synthesis of component 7.
SCHEME 4Synthetic pathway for compound 9.
SCHEME 5Synthesis of quinoline analogue 10.
SCHEME 6Synthesis of compound 11.
SCHEME 7Synthesis of compound 12.
Antioxidant activity of compounds 5–12.
| Sample | Absorbance |
|---|---|
| Standard | 1.03 |
| 5a | 0.00 |
| 5b | 0.14 |
| 5c | 0.00 |
| 5d | 0.26 |
| 6 | 0.00 |
| 7 | 0.00 |
| 9 | 0.38 |
| 10 | 0.00 |
| 11 | 0.22 |
| 12 | 0.29 |
Antibacterial activity of the screened compounds 5–12.
| Inhibition zone (mm) |
|
|
|
|
|
|---|---|---|---|---|---|
| Code no. | |||||
| Control | 0 | 0 | 0 | 0 | 0 |
| 5a | 12 | 9 | 8 | 10 | 9 |
| 5b | 3 | 0 | 0 | 0 | 0 |
| 5c | 0 | 0 | 0 | 0 | 0 |
| 5d | 7 | 9 | 17 | 12 | 12 |
| 6 | 0 | 0 | 0 | 0 | 0 |
| 7 | 0 | 0 | 0 | 0 | 0 |
| 9 | 18 | 1 | 4 | 19 | 10 |
| 10 | 17 | 10 | 17 | 18 | 11 |
| 11 | 10 | 7 | 1 | 6 | 8 |
| 12 | 10 | 20 | 13 | 18 | 0 |
| Standard |
|
|
|
|
|
| St. Result | 15 | 14 | 16 | 16 | 20 |
The binding energies (ΔGbind) of the docked standard drugs and compounds 5–12 and their intermolecular interactions with the active site of the target enzymes.
| Antioxidant | Antibacterial | |||||
|---|---|---|---|---|---|---|
| (ΔGbind) | Docked complex (amino acid–ligand) interactions | Distance (Å) | (ΔGbind) | Docked complex (amino acid–ligand) interactions | Distance (Å) | |
| Standard drug | −7.5 | H-bonds | −8.3 | H-bonds | ||
| Asn267:ND2―standard drug | 2.97 | Arg76:NH1― standard drug | 2.94 | |||
| Asn267:ND2―standard drug | 2.95 | His99:N― standard drug | 2.97 | |||
| π-cation interaction | Ser121:OG― standard drug | 2.95 | ||||
| Arg272:NH1―standard drug | 4.95 | Ile94:O― standard drug | 2.19 | |||
| Arg272:NH1―standard drug | 5.96 | Val97:O― standard drug | 2.06 | |||
| Arg272:NH1―standard drug | 5.98 | π-cation interaction | ||||
| π-Sigma interaction | Arg76:NH1― standard drug | 5.15 | ||||
| Pro264:CB― standard. Drug | 3.75 | Arg76:NH2― standard drug | 4.13 | |||
| 5a | −6.9 | H-bonds | −7.7 | H-bonds | ||
| Asn267:ND2―compound5a | 3.09 | Thr165:OG1―compound5a | 3.09 | |||
| Asn267:O―compound5a | 1.98 | Thr165:OG1―compound5a | 2.35 | |||
| π-cation interaction | π-cation interaction | |||||
| Arg272:NH1―compound5a | 5.98 | Arg76:NH2―compound5a | 4.28 | |||
| Arg272:NH2―compound5a | 4.30 | |||||
| 5b | −7.0 | H-bonds | −7.9 | H-bonds | ||
| Asn267:ND2―compound5b | 3.04 | Thr165:OG1―compound5b | 2.96 | |||
| Asn267:O―compound5b | 1.86 | Thr165:OG1―compound5b | 2.47 | |||
| π-cation interaction | Asp73:OD1―compound5b | 2.49 | ||||
| Arg272:NH1―compound5b | 5.97 | π-cation interaction | ||||
| Arg272:NH2―compound5b | 4.61 | Arg76:NH2―compound5b | 3.96 | |||
| 5c | −7.1 | H-bonds | −8.1 | H-bonds | ||
| Asn267:ND2―compound5c | 3.03 | Thr165:OG1―compound5c | 3.00 | |||
| Asn267:O―compound5c | 2.18 | Thr165:OG1―compound5c | 2.15 | |||
| Lys270:O―compound5c | 2.40 | π-cation interaction | ||||
| π-cation interaction | Arg76:NH1―compound5c | 5.27 | ||||
| Arg76:NH2―compound5c | 3.84 | |||||
| Arg272:NH2―compound5c | 4.49 | |||||
| 5d | −7.7 | H-bonds | −8.0 | H-bonds | ||
| Tyr128:OH―compound5d | 3.13 | Thr165:OG1―compound5d | 3.02 | |||
| π–π interaction | π-cation interaction | |||||
| Tyr132―compound5d | 5.00 | Arg76:NH2―compound5d | 3.89 | |||
| Phe236―compound5d | 4.34 | |||||
| Phe228―compound5d | 3.99 | |||||
| 6 | −7.9 | H-bonds | −8.6 | H-bonds | ||
| Asn267:ND2―compound6 | 3.19 | Gly77:N―compound6 | 3.08 | |||
| Lys270:O―compound6 | 2.22 | Asp73:OD2―compound6 | 1.85 | |||
| π-cation interaction | Asp73:OD1―compound6 | 2.32 | ||||
| Arg272:NH2―compound6 | 5.99 | |||||
| 7 | −8.2 | H-bonds | −7.8 | H-bonds | ||
| Tyr126:OH―compound7 | 3.15 | Thr165:OG1―compound7 | 3.11 | |||
| Tyr128:OH―compound7 | 3.14 | π-cation interaction | ||||
| π–π interaction | Arg76:NH2―compound7 | 3.91 | ||||
| Phe178―compound7 | 5.64 | Arg76:NH2―compound7 | 4.91 | |||
| Tyr126―compound7 | 4.38 | |||||
| Tyr126―compound7 | 4.38 | |||||
| Tyr126―compound7 | 4.76 | |||||
| Tyr126―compound7 | 5.12 | |||||
| 9 | −9.1 | H-bonds | −9.3 | H-bonds | ||
| Gly235:O―compound9 | 2.33 | Asn46:ND2―compound9 | 2.76 | |||
| π–π interaction | Gly77:N―compound9 | 2.82 | ||||
| Tyr132―compound9 | 5.83 | Thr165:OG1―compound9 | 3.08 | |||
| Tyr132―compound9 | 4.97 | Thr165:OG1―compound9 | 2.29 | |||
| Tyr132―compound9 | 3.76 | |||||
| Tyr132―compound9 | 3.63 | |||||
| Phe228―compound9 | 5.25 | |||||
| Phe228―compound9 | 4.46 | |||||
| Phe228―compound9 | 5.97 | |||||
| 10 | −8.0 | H-bonds | −8.3 | H-bonds | ||
| Lys270:O―compound10 | 2.14 | Asn46:ND2―compound10 | 2.84 | |||
| π-cation interaction | Gly77:N―compound10 | 2.87 | ||||
| Arg272:NH1―compound10 | 6.00 | Thr165:OG1―compound10 | 2.92 | |||
| Arg272:NH2―compound10 | 3.95 | π-cation interaction | ||||
| Arg76:NH1―compound10 | 5.98 | |||||
| Arg76:NH2―compound10 | 4.86 | |||||
| 11 | −7.7 | H-bonds | −7.6 | H-bonds | ||
| Asn267:ND2―compound11 | 3.20 | Asn46:ND2―compound11 | 3.18 | |||
| Lys270:O―compound11 | 2.27 | Gly77:N―compound11 | 2.65 | |||
| π-cation interaction | π-cation interaction | |||||
| Arg272:NH2―compound11 | 3.46 | Arg76:NH2―compound11 | 4.77 | |||
| 12 | −8.7 | π-cation interaction | −9.2 | H-bonds | ||
| Arg272:NH1―compound12 | 5.36 | Asn46:ND2―compound12 | 3.07 | |||
| Arg272:NH1―compound12 | 5.98 | Gly77:N―compound12 | 2.68 | |||
| Arg272:NH1―compound12 | 5.76 | π-cation interaction | ||||
| Arg272:NH1―compound12 | 5.94 | Arg76:NH2―compound12 | 4.39 | |||
| Arg76:NH2―compound12 | 4.05 | |||||
| π-Sigma interaction | ||||||
| Ile78:CG1―compound12 | 3.43 | |||||
FIGURE 1(A) 3D and (B) 2D representations of standard drug and the best docked compounds with 1DXO. H-bonds are represented in black dotted lines while pi-interactions are shown in orange lines. Colored balls with 3-letter code represented the amino acid residues of the target 1DXO.
FIGURE 2(A) 3D and (B) 2D representations of standard drug and the best docked compounds standard drug with 1JA6. H-bonds are represented in black dotted lines while pi-interactions are shown in orange lines. Colored balls with 3-letter code represented the amino acid residues of the target 1JA6.
List of ADME/T and physicochemical properties of standard drugs and compounds 5–12.
| MW (g/mol) | BBB+ | Caco2+ | HIA+ | logp | TPSA A2 | nON | nOHNH | RBs | N violations | AMES toxicity | Carcinogenicity | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference range | 180–500 | −3 to 1.2 | <25 poor >500 great | <25 poor >80 high | <5 | ≤140 | 2.0–20.0 | 0.0–6.0 | ≤10 | Nontoxic | Noncarcinogenic | |
| Tropoflavin | 254.24 | 0.50 | 90.57 | 98.5 | 2.97 | 70.67 | 4 | 2 | 1 | 0 | Nontoxic | Noncarcinogenic |
| Novobiocin | 612.63 | 0.82 | 85.84 | 76.04 | 3.93 | 200.02 | 13 | 6 | 9 | 2 | Nontoxic | Noncarcinogenic |
| 5a | 310.35 | 0.95 | 50.00 | 99.5 | 2.68 | 84.58 | 5 | 3 | 4 | 0 | Nontoxic | Noncarcinogenic |
| 5b | 344.80 | 0.95 | 64.25 | 99.4 | 3.34 | 84.58 | 5 | 3 | 3 | 0 | Nontoxic | Noncarcinogenic |
| 5c | 344.80 | 0.95 | 56.09 | 99.4 | 3.34 | 84.58 | 5 | 3 | 3 | 0 | Nontoxic | Noncarcinogenic |
| 5d | 324.38 | 0.95 | 55.64 | 99.5 | 2.99 | 84.58 | 5 | 3 | 3 | 0 | Nontoxic | Noncarcinogenic |
| 6 | 279.30 | 0.97 | 57.21 | 98.81 | 2.07 | 87.38 | 4 | 4 | 0 | 0 | Nontoxic | Noncarcinogenic |
| 7 | 279.30 | 0.94 | 57.85 | 98.91 | 3.14 | 58.56 | 3 | 2 | 0 | 0 | Nontoxic | Noncarcinogenic |
| 9 | 371.39 | 0.95 | 52.00 | 99.19 | 4.57 | 70.00 | 4 | 2 | 1 | 0 | Nontoxic | Noncarcinogenic |
| 10 | 405.84 | 0.97 | 60.53 | 96.95 | 4.92 | 79.53 | 5 | 2 | 3 | 0 | Nontoxic | Noncarcinogenic |
| 11 | 400.48 | 0.96 | 51.54 | 99.50 | 4.28 | 75.79 | 5 | 2 | 5 | 0 | Nontoxic | Noncarcinogenic |
| 12 | 372.38 | 0.96 | 79.08 | 99.27 | 3.47 | 96.02 | 6 | 3 | 1 | 0 | Nontoxic | Noncarcinogenic |
The pharmacokinetic and physicochemical properties of the molecules (5–12). The agreeable ranges are as follows: Mol wt.: (<500); %Human oral absorption: >80% high, <25% low. logp, logarithm of partition coefficient between n-octanol and water <5; TPSA, topological polar surface area ≤140; nON, number of hydrogen bond acceptors 2.0–20.0; nOHNH, number of hydrogen bond donors 0.0–6.0; RBs, number of rotatable bonds ≤10.